drugset / Trial / NCT00399477

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

NCT00399477

Phase 4 Completed 200 enrolled Teva Neuroscience, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: * Group 1 Patients using Azilect and no other therapy. * Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.

Timeline

Start
2006-10
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rasagiline Small molecule
Background Levodopa Small molecule
Background Pramipexole Unknown
Background Ropinirole Small molecule

Indications